跳至主要内容
临床试验/NCT01964885
NCT01964885终止3 期

Clinical Trial to Explore Benefit and Tolerability of IQP-AS-105 (Xaludicin®) in Subjects With Increased Susceptibility to Upper Respiratory Tract Infections

InQpharm Group2 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2013年10月最近更新:
适应症

试验速览

阶段
3 期
状态
终止
入组人数
140
试验地点
2
主要终点
Difference in severity of common cold symptoms for cold episodes between the two arms

研究概览

简要总结

IQP-AS-105, is a food supplement derived from garlic (Allium sativum). The objective of this study is to evaluate the possibilities of clinical use of IQP-AS-105 as a preventive medicine, based on its ability to enhance the immune system responses

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age 18-70 years
  • increased risk for infections - at least 4 cold episodes within 12 months
  • commitment to adhere to their accustomed diet and physical activity
  • women of child-bearing potential have to agree to use appropriate birth control methods
  • written consent of the subject to participate is a prerequisite for study participation

排除标准

  • acute / chronic upper airways disease
  • chronic cough of any origin
  • acute / chronic lower airways disease
  • any allergic reaction that may influence the study outcome (e.g. acute/chronic rhinitis)
  • history of nasal reconstructive surgery
  • presence of nasal ulcers or nasal polyps
  • severe nasal septum deviation or other condition that could cause nasal obstruction
  • congenital or acquired immunodeficiency disease (e.g. HIV infection)
  • severe organ or systemic diseases
  • body temperature above 37.5°C
  • suspected swine flu or influenza
  • vaccination against influenza or swine flu within 3 months prior to study start
  • stomach/gastrointestinal diseases
  • sleep disorder
  • psychiatric disorders
  • known sensitivity to the ingredients of the investigational product
  • intake of products that may influence the study outcome within the last 14 days prior to study start and during the study
  • analgesics , antibiotics or decongestant nose drops/spray, unless they are used as rescue medications
  • pregnancy or nursing
  • alcohol / drug abuse
  • simultaneous participation in another clinical trial or participation in a clinical trial within the last 30 days
  • insufficient compliance

结局指标

主要结局

Difference in severity of common cold symptoms for cold episodes between the two arms

时间窗: 12 weeks

Assessed by WURSS-21

次要结局

  • Incidence of viral infection(12 weeks)
  • Day and score value of the maximal WURSS-21 daily score(12 weeks)
  • Changes in special laboratory parameters in the subgroup(7 days)
  • Incidence of cold episodes(12 weeks)
  • Severity of cold symptoms at recurring (subsequent) episodes(12 weeks)
  • global evaluation of the benefit by the subjects / investigators(12 weeks)
  • Duration of cold episodes(12 weeks)
  • Severity of cold symptoms over the first 7 days of the episode(12 weeks)
  • Severity of cold symptoms over the first 4 days of the episode(12 weeks)
  • Use of rescue medication(12 weeks)
  • Number of re-infections(12 weeks)
  • Severity of cold episodes during the 4 week follow-up period(12 weeks)
  • Changes in cytokine production in the subgroup(7 days)
  • Severity of cold somptoms from the date of the maximal WURSS-21 daily score, for 4 days following thereafter(12 weeks)
  • Number of days on sick leave related to cold episodes(12 weeks)
  • Severity of cold symptoms at first episode(12 weeks)
  • Global assessment of tolerability by subjects/investigators(12 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验